EDGAR Filing Documents for 0001636050-20-000029

Form 8-K - Current report:

SEC Accession No. 0001636050-20-000029

Filing Date

2020-06-10

Accepted

2020-06-10 06:02:36

Documents

Period of Report

2020-06-10

Items

Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	axovant8-k0609201.htm	8-K	38806
2	EX-99.1	axovantexhibit991.htm	EX-99.1	131509
3		image01.jpg	GRAPHIC	5086
	Complete submission text file	0001636050-20-000029.txt		178860

Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036

Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708

Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37418 | Film No.: 20953437
SIC: 2834 Pharmaceutical Preparations